Another Hot Australian Biotech: Is Biotron Right for Your Portfolio?[Ed. Note: Here is our second installment from Dr. KSS, formerly known as “karmaswimswami” in Gumshoe discussion threads. Dr. KSS has agreed to our trading and disclosure restrictions, and he’s not offering you personal investment or medical advice. As with all of our columnists, we don’t assign topics or opinions and do just a bit of light […]
Articles
- Most Relevant
- Most Recent
#NeverAgain is a new American student-led organization that advocates for tighter regulations to prevent gun violence. It was started in February, 2018, by 20 students at Marjory Stoneman Douglas High School in Parkland, Florida, after 17 people were murdered by a shooter armed with an AR-15 style semi-automatic rifle, and now has tens of thousands […]
We’ll do a quickie for you today — a reader sent this question in, and was kind enough to even send the answer along with it, so we double-checked, fed his info through the Thinkolator, and I’ll share it with you. The pitch is from Chris Wood, dangling some bait to entice subscribers to his […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own. Enjoy!] In the Saturday morning Looney Tunes many of us saw as children, one trope always stuck with me: that of the grand piano falling from way up high and crashing, splintering itself. There’s a […]
We are right around the peak year for “number of people entering retirement” right now, and the stock market remains richly valued and a little nerve-wracking for the folks who are just beginning to think about living off of their investments… so I expect we’ll continue to see more pitches and promises about income investments […]
Yes, the title of this article is misleading, dangerous crap. Sorry, but I just took it directly from the ad — the ad I’m writing about today is from Patrick Cox for his Breakthrough Technology Alert, a relatively expensive ($895) newsletter that focuses on, well, breakthrough technologies, mostly stocks that we’d classify as biotechs or […]
The world of psychedelics was briefly exciting for investors, mostly back around 2019-2020 or so, when everyone was looking for the next version of the cannabis bull market (remember that?)… and as potential for legalization of some drugs, like psilocybin (“magic mushrooms”), seemed to be in the wind, and old hallucinogenic or psychedelic compounds were […]
I was all set to write up a little teaser from someone else, but then this latest pitch from the Motley Fool crossed my desk and, well, it’s exactly the kind of thing that Gumshoe readers are going to be asking about. So look out below, here some some answers! The tease is from Joe […]
[ed note: Michael Jorrin, who I like to call “Doc Gumshoe”, is a longtime medical writer (not a doctor) who shares his thoughts with us from time to time, generally on non-financial topics in health and medicine (as today, though he mentions a couple publicly traded companies). His words and opinions are his own.] Let’s […]
OK, so let me just warn you up front: The latest ad from Nancy Zambell for her new Buried Treasure under $10 newsletter has a lot of, well, hooey in it. But really, doesn’t that just make it more fun? Here’s how the hype begins: “Buffett has sunk $2 billion into the next Wal-Mart Here’s […]
The one area of the web that has as many “self help” and “miracle solutions” newsletters (and marketing teasers) as personal finance is health — the investing newsletters promise eternal wealth, and the health newsletters promise eternal life (or something dang close). Readers ask us about the crazy marketing for these health newsletters all the […]
This isn’t the first time we’ve seen a teaser ad that says you can “collect a $X,000 payday” — and it’s obviously appealing, there aren’t many among us who don’t find their eyes drifting toward a headline like “$6,500 payday,” even if, like your friendly neighborhood Gumshoe, you light your cigars with $100 bills. OK, […]
Sometimes when I’m choosing which ad to cover on a given day it’s based on the number of questions I’ve gotten, or the number of times we’ve seen the ad in the past few days… and sometimes it’s based on something that just feels like something interesting. Today it’s the latter… because Brett Aitken and […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He choses his own topics, and his words and opinions are his own. Part one of this series is here if you missed it. Enjoy!] “The heat was hot and the ground was dry but the air was full of sound. I’ve […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, writes for us a couple times a month on medicine and health issues. He is not a physician, but explains the science and the data well, and helps provide some background understanding and perspective that often benefits both investors and folks who are attentive […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
While we wait to see what Berkshire Hathaway’s quarter looked like, how’s the rest of the portfolio holding up? Holy Cow, Starbucks (SBUX)! Haven’t seen that stock take this big of a pop after earnings in a long time, and sentiment seems to have changed so quickly to a “this is a safe capital return […]
Today we have the pleasure of yet another ad that includes a made-up name that sounds official … This time, it’s the “100-F Document” — something that is filed in Washington, D.C. that will give you inside information into a company’s troubles, and let you bet against the company before it makes headlines. And it’s […]
A quickie for you today, since a few folks have asked… One of the seemingly 10,000 Banyan Hill newsletters is being teased today, and the bait they’re dangling is that Jeff Yastine is about to recommend a stock to his subscribers on Wednesday… which is tomorrow, so we’ll be brief so you can have some […]
Dan Amoss has added a new twist to the “100-F” teaser that I wrote about here a couple months ago, so I’m adding a new twist as well. He’s now calling this “Retirement Recovery Insurance,” and using examples of folks like laid-off auto workers who are using this strategy to make more money than they […]
Alpha Contracts! That’s what’s being teased by the Agora Financial folks these days, all as part of a pitch for Zachary Scheidt’s Contract Income Alert. And they’ve been teased before, but I had a bunch of readers pile on with questions this week — probably thanks to that new “July 22” deadline — so I […]
When the Trade War started heating up with China, you knew it would only be a matter of time before “rare earths” started coming into play again. These are the rare earth elements, sometimes called rare earth metals or rare earth magnets, that are way down the periodic table, often found in uranium mines, and […]
Today we take a gander at a pitch from Mark Skousen, who has been a newsletter guy for decades with his Forecasts & Strategies newsletter (he’s also an itinerant economics professor, and runs the big “freedomfest” conference in Las Vegas each year, among other things). And the headline of his latest “presentation” pretty well sums […]
The jobs report from ADP was frightening on Wednesday, bringing more fear that the trade war uncertainty and/or some shift in sentiment is cutting business spending, and it seems to be contributing to the rapid “narrative shift” that has happened this year — whereas we were all shocked that the Fed would even consider cutting […]
We see “Amazon can’t beat this one” ads every now and again for retailers — that was part of Oxford Club’s push for Planet Fitness earlier this week, for example — but this one is generating quite a few questions… and I haven’t written about one of Hilary Kramer’s ads for a while, so it […]
The Oxford Club has been recruiting subscribers by dangling the promise of their “$3 Secret Stock” for almost a year now, and those ads are still rolling around the interwebs… but it looks like they’ve finally got a new recruitment tool: The “Next American Mega-Brand.” So what is it? Let’s check out the ad, see […]
I’ve been seeing ads for the Motley Fool’s Stock Advisor Canada service recently that catch the eye… mostly because they promise what we all want, the ability to find that one stock that will turn your small investment into a life-changing fortune. They do this by starting with the story of “Forty-dollar Frank” …. “When […]
I have no idea what’s going to happen in the market today, but perhaps if I spend my time looking into a teaser pitch from a new newsletter I’ll be too busy to obsess over my portfolio and do something dumb during the trade war panic gyrations. Sound good? Want to join me? Great! The […]
I guess this is shaping up to be another “marijuana week” here at Stock Gumshoe… this latest pitch talks up a chance at making five times your money on “a marijuana stock opportunity that almost NO ONE is talking about yet.” Which, of course, is music to our ears — we do love a good […]
The other four stocks teased by Jimmy Mengel for his Crow’s Nest newsletter aren’t necessarily as interesting (story wise) as the one we looked at yesterday… but I promised to try to ID them for you, so let’s jump right in. I should let you know, first, that some of these are guesses. As usual, […]
We turn once again, dear friends, to my favorite kind of newsletter teaser ad: the promotion of “one little company” as the linchpin investment for exposure to a huge global trend. This time, it’s Alex Koyfman promoting his Penny Stock Millionaire newsletter ($999/year) by promising to reveal the name of a little “Super Battery” company […]
In case you’ve been living under a rock, the hot IPO news this year is that both Lyft and Uber are going public (along with other mega-IPOs Pinterest (PINS) and, probably, Palantir) — Lyft (LYFT) is already trading and generated a lot of excitement on the first day, though came back down sharply almost immediately, […]
I’ve been meaning to check in on one of the few mutual funds that I’ve written in detail about for you, so in the absence of any other big portfolio moves we’ll take a minute for that today. DoubleLine Shiller Enhanced CAPE (DSEEX) is a “better mousetrap” kind of fund, which should make us start […]
As we close in on the end of the first quarter, it’s time to release some more data — I just posted the 2019 teaser tracking spreadsheet for you, you can find it on the tracking page along with all our previous years and use it both to see what we’ve been covering so far […]
In case you’ve been living under a rock, the hot IPO news this year is that both Lyft and Uber will be going public very soon — Lyft, in fact, should hit the public markets for the first time on Friday after setting a price for the IPO tomorrow, and their larger competitor will be […]
Today we’ve got a quickie for you, in response to a couple questions about the Cabot Top Ten Trader teaser pitch that came out over the weekend. Top Ten Trader ($137/year) is a short-term newsletter edited by Mike Cintolo, he basically sifts out ten of their favorite growth stocks each week, and I think they’re […]
This pitch about “Federal Rent Checks” has been circulating for quite a while, and it’s still being mailed out with a July 2018 date under the signature (I got a few questions about it just this week), so I decided to take a second look. And what do you know, there has been a LOT […]
Another day, another promise of imminent riches from a biotech clinical trial! This time it’s from Ray Blanco, who has made many such promises in his ads, and the pitch is all about a “bio switch” that has the potential to “end diabetes, plus heart & kidney disease (with a twice-a-day pill).” What more could […]
Any one have an idea as to what stock Ray Blanco is referring to in his ”Breakthrough Technology Alert” teaser?
Heydy ho, investing friends! I finally wrap up my Annual Review this week by covering the final three names… and I’ve also got a bunch of other updates to share with you, along with one add-on buy and one brand-new holding for the Real Money Portfolio… enjoy! We’ll start with the completion of the annual […]